PT  - JOURNAL ARTICLE
AU  - van Doremalen, Neeltje
AU  - Bushmaker, Trenton
AU  - Morris, Dylan H.
AU  - Holbrook, Myndi G.
AU  - Gamble, Amandine
AU  - Williamson, Brandi N.
AU  - Tamin, Azaibi
AU  - Harcourt, Jennifer L.
AU  - Thornburg, Natalie J.
AU  - Gerber, Susan I.
AU  - Lloyd-Smith, James O.
AU  - de Wit, Emmie
AU  - Munster, Vincent J.
TI  - Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1
AID  - 10.1101/2020.03.09.20033217
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.09.20033217
4099  - http://medrxiv.org/content/early/2020/03/10/2020.03.09.20033217.short
4100  - http://medrxiv.org/content/early/2020/03/10/2020.03.09.20033217.full
AB  - HCoV-19 (SARS-2) has caused >88,000 reported illnesses with a current case-fatality ratio of ∼2%. Here, we investigate the stability of viable HCoV-19 on surfaces and in aerosols in comparison with SARS-CoV-1. Overall, stability is very similar between HCoV-19 and SARS-CoV-1. We found that viable virus could be detected in aerosols up to 3 hours post aerosolization, up to 4 hours on copper, up to 24 hours on cardboard and up to 2-3 days on plastic and stainless steel. HCoV-19 and SARS-CoV-1 exhibited similar half-lives in aerosols, with median estimates around 2.7 hours. Both viruses show relatively long viability on stainless steel and polypropylene compared to copper or cardboard: the median half-life estimate for HCoV-19 is around 13 hours on steel and around 16 hours on polypropylene. Our results indicate that aerosol and fomite transmission of HCoV-19 is plausible, as the virus can remain viable in aerosols for multiple hours and on surfaces up to days.Competing Interest StatementThe authors have declared no competing interest.Funding Statement. This research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). JOL-S and AG were supported by the Defense Advanced Research Projects Agency DARPA PREEMPT # D18AC00031, and JOL-S was supported by the U.S. National Science Foundation (DEB-1557022) and the Strategic Environmental Research and Development Program (SERDP, RCâ€26635) of the U.S. Department of Defense.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata is available upon request